

Catalog Number: CM04301

## 产品信息

**Catalog Number:**  
CM04301

**CAS号:**  
882366-16-7


**分子式:**  
 $C_{14}H_{13}ClN_2O_4S$

**主要靶点:**  
GPCR19

**主要通路:**  
G蛋白偶联受体

**分子量:**  
340.78

**溶解度:**  
DMSO:150 mg/mL (440.17 mM)



## 体内活性

Stimulation of cholangiocytes with TLCA following by SBI-115 treatment resulted in dose-dependent (by 32–48%) inhibition of cell proliferation.

## 细胞实验

cAMP was detected by the Bridge-It cAMP designer cAMP assay. Cholangiocytes (10,000/well) were incubated with TLCA, OA, C1 and C2 (all, 25  $\mu$  M), SBI-115 (100 and 200  $\mu$  M) and pasireotide (20  $\mu$  M) for 15–30 min. Doses of drugs were chosen based on published data or dose ranging (SBI-115). Cell proliferation was determined by CellTiter 96 Aqueous One Solution Cell Proliferation Assay and by cell counting using the Cellometer Auto4 cell counter. Cholangiocytes (2500 cells/well) were grown for 24–48 hours and then treated with TGR5 agonists (all, 25  $\mu$  M), SBI-115 (100 and 200  $\mu$  M) and pasireotide (20  $\mu$  M) for additional 24 hours. Alterations in cell proliferation after treatment were expressed as percent change compared to un-treated cholangiocytes in which cell proliferation was considered to be equal 100%.

## 描述

SBI-115 is an antagonist of TGR5. SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5

## 储存

Powder: -20°C for 3 years | In solvent: -80°C for 2 years